文献速递系统性红斑狼疮

Aim2与Ube2i偶联通过SUMO化抑制系统性红斑狼疮干扰素特征

Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2021-07-07

该研究在降植烷诱导的雌性小鼠模型中探索Aim2在系统性红斑狼疮(SLE)中的作用,发现Aim2缺失(而非Asc缺失)加重SLE样表现,包括肾脏免疫细胞浸润和I型干扰素特征增强,且阻断Ifnar1信号可减轻病情。机制上Aim2结合Ube2i,通过SUMO化抑制I型干扰素表达,Aim2缺失降低细胞SUMO化水平,从而增强I型干扰素特征和肾脏病变。

要点

  • Aim2缺失加重降植烷诱导的SLE小鼠模型肾脏病变和I型干扰素特征。
  • 阻断Ifnar1信号可减轻Aim2缺失小鼠的SLE严重程度。
  • Aim2通过结合Ube2i促进SUMO化,抑制I型干扰素表达。

核心结论

  • Aim2在Ube2i介导的SUMO化抑制I型干扰素生成中起关键作用,Aim2-Ube2i轴可作为SLE干预的新靶点。

研究设计与样本

  • 雌性野生型、Aim2-/-、Aim2-/-Ifnar1-/-、Aim2-/-Rag1-/-和Asc-/-小鼠(8-10周龄)接受单次腹腔注射500 μl降植烷或生理盐水,每周监测生存两次,持续6个月。

主要发现

  • Aim2缺失(而非Asc缺失)导致降植烷处理小鼠SLE加重。
  • Aim2-/-小鼠肾脏免疫细胞浸润和I型干扰素特征增加,与狼疮严重程度一致,阻断Ifnar1信号可减轻。
  • Aim2-/-小鼠肾小球病变涉及适应性免疫细胞。
  • 即使无降植烷处理,Aim2-/-小鼠肾脏浆细胞样树突状细胞较对照显著增加。
  • 转录组分析显示Aim2缺失在早期发育阶段即增强肾脏I型干扰素诱导基因表达。

临床怎么用

  • Aim2-Ube2i轴可能成为SLE治疗的新干预靶点,尤其针对I型干扰素通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) involves kidney damage, and the inflammasome-caspase-1 axis has been demonstrated to promote renal pathogenesis. The present study was designed to explore the function of the Absent in Melanoma 2 (Aim2) protein in SLE. METHODS: Female wild-type Aim2-/- , Aim2-/- Ifnar1-/- , Aim2-/- Rag1-/- , and Asc-/- mice ages 8-10 weeks received 1 intraperitoneal injection of 500 μl pristane or saline, and survival of mice was monitored twice a week for 6 months. RESULTS: The absence of Aim2, but not Asc, led to enhanced SLE in mice that received pristane treatment. Increased immune cell infiltration and type I interferon (IFN) signatures in the kidneys of Aim2-/- mice coincided with severity of lupus, which was alleviated by blockade of Ifnar1-mediated signal. Adaptive immune cells were also involved in the glomerular lesions of Aim2-/- mice after pristane challenge. Importantly, even in the absence of pristane, plasmacytoid dendritic cells in the kidneys of Aim2-/- mice were significantly increased compared to control animals. Accordingly, transcriptome analysis revealed that Aim2 deficiency led to enhanced expression of type I IFN-induced genes in the kidneys even at an early developmental stage. Mechanistically, Aim2 bound ubiquitin-conjugating enzyme 2i (Ube2i), which mediates sumoylation-based suppression of type I IFN expression deficiency of Aim2 decreased cellular sumoylation, resulting in an augmented type I IFN signature and kidney pathogenesis. CONCLUSION: The present study demonstrates a critical role for Aim2 in an optimal Ube2i-mediated sumoylation-based suppression of type I IFN generation and development of SLE. As such, the Aim2-Ube2i axis can thus be a novel target for intervention in SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lu A, Wu S, Niu J, et al. Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021. PMID: 33559374. doi:10.1002/art.41677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。